Monkeypox virus, a member of the Orthopoxvirus genus, has reemerged as a pathogen of global health concern, particularly following outbreaks beyond its traditional endemic regions in Central and West Africa. Unlike the eradicated smallpox virus, monkeypox continues to cause sporadic outbreaks with human-to-human transmission, raising alarm within public health communities worldwide. The development of safe and effective vaccines tailored to the unique virological and immunological characteristics of monkeypox is therefore a pressing scientific objective.

The study, conducted by Li and colleagues and published in Nature Communications, employs a novel multivalent mRNA platform designed to encode multiple key antigens of the monkeypox virus. This approach stands in contrast to classical vaccine constructs by harnessing synthetic messenger RNA technology, which enables rapid design, scalable manufacture, and potent antigen expression in vivo. The vaccine’s multivalent nature aims to elicit a broad immune response capable of targeting diverse epitopes simultaneously, enhancing the prospect of robust and durable immunity.

Researchers engineered the mRNA constructs to encode several structural proteins of monkeypox virus, each carefully selected based on their immunodominance and role in viral entry and replication. This multiepitope strategy is anticipated to stimulate both arms of the adaptive immune system: B-cell mediated humoral responses and T-cell driven cellular immunity. Such comprehensive immune activation is critical for thwarting virus propagation and facilitating viral clearance.

In vivo experiments utilized a well-established murine model that recapitulates key aspects of monkeypox infection in humans. Immunized mice exhibited strong antigen-specific antibody responses as measured by enzyme-linked immunosorbent assay (ELISA) and neutralization assays, indicating effective humoral immunity. Notably, the neutralizing antibodies generated were capable of inhibiting viral infectivity in vitro, suggesting the vaccine’s potential to prevent initial viral entry into host cells.

Complementing the humoral findings, the vaccine induced significant T-cell responses characterized by elevated frequencies of interferon-gamma (IFN-γ) producing CD4+ and CD8+ T cells. Such cellular immunity is pivotal in controlling viral replication and providing long-lasting protection. Flow cytometric analyses revealed enhanced activation and proliferation of these lymphocyte subsets post-vaccination, underscoring the immunogenic robustness of the mRNA formulation.

Crucially, challenge studies demonstrated that vaccinated mice were protected from lethal monkeypox virus exposure. Animals receiving the multivalent mRNA vaccine displayed markedly reduced viral loads in target organs including the lungs and spleen, as quantified by quantitative PCR. This reduction was accompanied by amelioration of clinical symptoms and increased survival rates relative to unvaccinated controls, underscoring the vaccine’s protective efficacy.

The safety profile of the mRNA vaccine was also rigorously evaluated. Vaccinated animals tolerated the regimen well, with no observable adverse events or histopathological abnormalities in examined tissues. This favorable tolerability aligns with emerging data supporting the safety of mRNA vaccines across various infectious diseases, reinforcing their suitability for rapid pandemic response applications.

Of particular interest is the modular nature of the mRNA platform employed, which may facilitate adaptation to viral variants or related orthopoxviruses by simply modifying the encoded antigenic sequences. This flexibility is highly advantageous in light of the genetic plasticity observed in viral pathogens and the ongoing evolution of monkeypox virus strains. The ability to swiftly update vaccine candidates could prove invaluable in mitigating future outbreaks.

Moreover, the scalable manufacturing capabilities inherent to mRNA technology offer a practical pathway to mass production, circumventing some of the limitations associated with traditional live-attenuated or subunit vaccines. The relatively rapid development timelines afforded by mRNA constructs may translate into accelerated clinical testing and deployment, a necessity for staying ahead of emergent threats.

This study also contributes to the growing body of evidence supporting mRNA vaccines as a versatile platform not only for viral infections but potentially for other disease modalities. The success seen with SARS-CoV-2 vaccines has paved the way for such innovative efforts, and the findings of Li et al. further validate the broad applicability of this technology.

Beyond the immunological outcomes, the research employed advanced bioinformatics and structural modeling to optimize antigen design, ensuring the encoded proteins maintained conformational epitopes critical for immune recognition. This rational design strategy enhances the likelihood of eliciting potent neutralizing antibodies, an essential consideration given the antigenic complexity of orthopoxviruses.

In sum, this investigation delineates a compelling preclinical proof-of-concept for a multivalent mRNA vaccine against monkeypox virus, highlighting its immunogenicity, efficacy, and safety within an experimental setting. These encouraging results warrant further development and evaluation in higher-order animal models and ultimately human clinical trials, aiming to fill an unmet need in infectious disease preparedness.

As global interconnectedness facilitates the rapid spread of emerging pathogens, proactive vaccine development initiatives such as this will be instrumental in safeguarding public health. The integration of cutting-edge molecular technologies with immunological insights embodies a promising paradigm shift that transcends conventional vaccine paradigms.

Future research directions may explore combination strategies involving this mRNA vaccine with existing smallpox vaccines or antiviral therapeutics, evaluating synergistic effects that could enhance protection. Additionally, longitudinal studies assessing the durability of immune memory induced by the vaccine will be vital to determine the need for booster doses.

This innovative work by Li and colleagues thus positions mRNA vaccine technology at the forefront of the fight against monkeypox virus and potentially other orthopoxviral threats, marking a significant advance toward comprehensive epidemic control and prevention strategies.

Subject of Research: Development and evaluation of a multivalent mRNA vaccine targeting monkeypox virus infection.

Article Title: A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection.

Article References:
Li, Y., Cheng, L., Jiang, L. et al. A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection. Nat Commun 16, 7373 (2025). https://doi.org/10.1038/s41467-025-61699-w

Image Credits: AI Generated

Hepatitis E virus is a small, non-enveloped, single-stranded RNA virus belonging to the Hepeviridae family. Previously, genotypes 1 to 4 have been well-documented in causing human infection with varied transmission routes, including-contaminated drinking water and zoonotic contact with animal reservoirs. However, rat HEV, initially isolated from rodents and thought to be limited to these animal hosts, has now been implicated in human infections with significant frequency and clinical consequence. This revelation positions rat HEV as an emerging pathogen with a substantial spillover burden—meaning it crosses the species barrier more readily than previously recognized.

Through a comprehensive surveillance study encompassing several geographic regions with high rodent densities, the research team employed serological assays alongside molecular techniques, including RT-PCR and genome sequencing, to detect rat HEV exposure and active infections in human cohorts. Intriguingly, the data indicated that a significant proportion of unexplained cases of acute hepatitis in these populations were linked to rat HEV exposure. The findings disrupt the prevailing notion that rat HEV poses minimal human risk and imply that the virus is silently circulating in humans more widely than anticipated.

The molecular characterization of the rat HEV strains isolated from human subjects unveiled distinct genetic signatures closely related, yet not identical, to classical rodent HEV strains. Phylogenetic analyses suggest ongoing adaptive evolution, likely driven by host-specific immune pressures, which may facilitate enhanced infectivity or replication efficiency in humans. Such genetic plasticity underlines the virus’s capacity to overcome interspecies transmission barriers and establish productive infections.

Clinically, rat HEV infection in humans manifests with symptoms ranging from mild, self-limiting hepatitis to severe liver dysfunction in more vulnerable individuals. Particularly concerning is evidence of the virus causing chronic infections in immunocompromised patients, a phenomenon reminiscent of genotype 3 HEV strains known for establishing persistence. Elevated alanine aminotransferase (ALT) levels and jaundice were common clinical findings, corroborating the hepatotropic nature of these infections. These clinical insights necessitate the inclusion of rat HEV screening in differential diagnoses of viral hepatitis, particularly when traditional hepatitis viruses are not detected.

The modes of transmission for rat HEV to humans are complex and multifactorial. Given the peridomestic nature of rodent populations, transmission likely involves direct exposure to rat excreta, consumption of contaminated food or water, or environmental contact within urban and rural settings. The study underscores the role of poor sanitation, close human-rodent proximity, and ecological factors facilitating viral persistence and human exposure risks. Importantly, no evidence currently suggests person-to-person transmission of rat HEV, distinguishing its epidemiology from that of other human HEV genotypes.

From an immunological perspective, the human immune response to rat HEV is not yet fully elucidated. Early serological results demonstrate variable antibody titers against rat HEV antigens, indicating that some level of immunogenicity exists but may be insufficient to confer lasting protection or prevent reinfection. The identification of viral epitopes recognized by neutralizing antibodies opens avenues for vaccine development and seroepidemiological tools necessary for public health surveillance.

The public health implications of these findings are profound. Rat HEV should now be considered an emerging zoonotic threat, particularly in metropolitan areas with dense rodent populations. Previous assumptions downplaying the virus’s relevance to human health must be reevaluated in light of this robust evidence. Intervention strategies—including improved rodent control, sanitation measures, and targeted public awareness—are urgently required to mitigate infection risk. Moreover, healthcare systems must adapt diagnostic protocols to include rat HEV screening for unexplained hepatitis cases.

Environmental virology aspects of the study provide further insight into viral persistence outside hosts. Rat HEV is shown to remain viable in water sources for extended periods, withstanding variable temperature and pH conditions encountered in urban wastewater systems. This environmental resilience enhances its transmission potential, especially in areas with inadequate sewage treatment infrastructure. These findings sharpen the focus on the intersection of environmental hygiene and zoonotic viral emergence.

Importantly, this research advances the broader concept of “One Health,” emphasizing the interconnectedness of human, animal, and environmental health domains. It underscores the necessity of interdisciplinary collaborations encompassing virology, ecology, epidemiology, and clinical medicine to address complex zoonotic infections. The rat HEV paradigm exemplifies the hidden viral threats lurking at the human-wildlife interface and challenges existing paradigms of infectious disease surveillance.

Future research must prioritize elucidating the molecular determinants governing rat HEV host specificity and pathogenicity. Animal models replicating human infection would facilitate mechanistic studies exploring viral entry, replication, immune evasion, and pathogenesis pathways. In parallel, longitudinal cohort studies tracking seroconversion and clinical outcomes will better define the disease burden and aid in risk stratification.

In conclusion, the identification of a substantial spillover burden of rat HEV in humans constitutes a paradigm shift in the understanding of hepatitis E epidemiology. This novel zoonotic threat demands immediate attention from researchers, clinicians, and public health officials to avert potential outbreaks and manage existing infections effectively. Integrated surveillance programs, coupled with enhanced diagnostic capabilities and preventive measures, will be indispensable tools in combating this emerging viral challenge. As the landscape of infectious diseases evolves, so too must our responses to ensure global health security against pathogens crossing species barriers from rodents to humans.

Subject of Research: Zoonotic transmission and human infection burden of rat hepatitis E virus (rat HEV).

Article Title: Substantial spillover burden of rat hepatitis E virus in humans.

Article References:

Chen, Z., Wang, L., Zhang, Y. et al. Substantial spillover burden of rat hepatitis E virus in humans.
Nat Commun 16, 4038 (2025). https://doi.org/10.1038/s41467-025-59345-6

Image Credits: AI Generated